Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
chronic kidney disease
Pharma
AZ's Ultomiris hits goal in ph. 3 IgAN trial
AstraZeneca's Ultomiris has delivered in a phase 3 trial in IgAN, setting up the C5 inhibitor for potential approval in a 5th indication.
Kevin Dunleavy
Apr 21, 2026 10:35am
Bayer tees up Kerendia for major CKD label expansion
Mar 16, 2026 9:46am
Esperion pays $75M for Corstasis and FDA-approved nasal spray
Mar 3, 2026 8:40am
In Super Bowl ad, Boehringer is on a mission to up uACR testing
Jan 28, 2026 8:40am
FDA safety probe, Otsuka, ADC patent fight—Fierce Pharma Asia
Dec 5, 2025 8:45am
Otsuka wins FDA nod in ever-more-crowded kidney disease space
Nov 26, 2025 11:10am
